Gill Measure Expands Alzheimer’s Treatment Coverage for State Employees

CHICAGO – Qualified state employees will have greater access to new and effective Alzheimer’s Disease treatments under a recently signed law spearheaded by state Rep. Mary Gill, D-Chicago.

“New Alzheimer’s treatments coming to market are a game changer in improving the wellbeing of patients, but it’s critical they receive access early in their diagnosis to benefit,” Gill said. “This measure is an important step forward for those covered under the State Employees Group Insurance Program, but I believe we need to go further and expand coverage for everyone. I appreciate the advocacy from the Alzheimer’s Association, and look forward to continued conversations on how we can bring effective treatment to more residents sooner.”

Gill led House passage of Senate Bill 3318, which will require the State Employees Group Insurance Program to provide coverage for all U.S. Food and Drug Administration (FDA)-approved treatments that slow the progression of Alzheimer’s Disease and related dementias. Treatment must be determined to be medically necessary by a licensed physician, and diagnostic testing must also be covered. Less costly, “fail first” step therapies are specifically prohibited by the measure in favor of immediately using the prescribed treatment that is expected to be more beneficial.

Senate Bill 3318 passed the General Assembly with bipartisan support, and was recently signed into law. The measure takes full effect July 1, 2025.

For more information, please contact RepMaryGill@gmail.com.